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Abstract 
Background: Hemophilia B which refers to the deficiency or functional 
defect of factor IX (FIX) is typically an X-linked bleeding condition that 
arises from heterogeneous mutations of the FIX gene (F9). The number of 
hemophilia cases in Iran is considerable and currently, about 1118 Iranian 
patients are suffering from hemophilia B, although a small number of them 
underwent genetic investigations. Here we assessed molecular defects and 
also laboratory and clinical findings of 10 Iranian cases with hemophilia B.  
Materials and Methods: A total of 10 cases with hemophilia B were 
enrolled in the study. Patients were clinically examined by a hematologist and 
their previous medical documents were surveyed carefully. Routine 
coagulation tests and FIX activity and antigen assays were performed for the 
studied patients. Genotyping of F9 for identifying genetic mutations was 
conducted by the Sanger sequencing method following PCR amplification of 
the promoter region and all the eight exons of the F9 gene.  
Results: The mean age of patients was 4 years (9 months to 16 years) and 
consanguinity was reported in 80% of cases. Patients were commonly 
manifested by hematoma (90%), epistaxis (80%), and hemarthrosis (70%) 
and the severity of the disorder was severe (70%) or moderate (30%). In 
nine out of 10 patients a genetic defect in F9 gene we detected including 
three missense (c.304T>C, c.1007T>A, c.191G>A) and three nonsense 
mutations (c.892C>T, c.880C>T, c.1113C>A). Based on the FIX variant 
database (http://www.factorix.org), five mutations have been reported 
previously, but mutation c.1007T>A (p.Ile336Asn) seems to be a novel 
mutation.  
Conclusion: Our results indicated the heterogeneous molecular defects of 
hemophilia B in Iran, as recorded in the FIX mutation database. Moreover, 
no specific genotype-phenotype association was observed in studied 
subjects.  




Please cite this article as: Shakouri M, Hosseini MS, Dorgalaleh A, Shahidi M, Zaker F. Complete Genotype and Clinical Phenotype of 
Hemophilia B: A Study on Iranian Patients. J Cell Mol Anesth. 2021;6(1):3-8. DOI: https://doi.org/10.22037/jcma.v6i1.33722  
 
Shakouri et al.                               Complete Genotype and Clinical Phenotype of Hemophilia B: A study on Iranian Patients 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
4 
Introduction 
Coagulation factor IX (FIX) is a vitamin K-dependent 
serine protease with a critical role in the coagulation 
cascade. Quantitative deficiency or functional defect 
of FIX which is known as Hemophilia B is a 
hemorrhagic disorder with an approximate prevalence 
of one in 30,000 male infants, much less frequent than 
hemophilia A (one in 5,000 males) (1). The disorder 
is typically hereditary with an X-linked recessive 
manner of inheritance, although about 30% of cases 
result from sporadic mutations (2). Bleeding from 
joints and soft tissues is the predominant clinical 
picture of hemophilia B, as of hemophilia A (3), and 
in some patients disabling arthropathy may occur as a 
consequence of recurrent joint bleedings (2). The 
disorder originates from mutations affecting the FIX 
gene (F9). F9 gene which spans 33.5 kb maps to the 
long arm of the X chromosome (Xq27.1) and contains 
eight exons. The transcribed mRNA with 2.8 kb 
length encodes 461 amino acids as a precursor 
polypeptide which then undergoes posttranslational 
modifications (4). These modifications include γ-
carboxylation of the initial Glu residues, 
glycosylation, hydroxylation, and phosphorylation. 
Furthermore, the signal peptide and the propeptide 
sequences are removed which then result in a mature 
zymogen with 415 residues and 57kDa molecular 
weight (5). FIX contain several domains including a 
Gla domain at the N-terminal region, a hydrophobic 
stack, two epidermal growth factor (EGF)-like 
domains, an activation peptide, and a C-terminal 
serine protease domain. In the presence of Ca2+, 
inactive FIX can be cleaved and converted to active 
FIX (FIXa) through extrinsic or intrinsic pathways by 
tissue factor/FVIIa or FXIa, respectively (5).  
Iran has a high rate of hemophilia patients and 
based on the 2019 global survey of the World 
Federation of Hemophilia (WFH), a total of 10030 
patients with hemophilia has been reported in Iran, 
among which 1118 patients are diagnosed with 
hemophilia B (5271 patients with hemophilia A and 
3641 cases with unknown type hemophilia) (6). 
Although several studies have been performed on 
different aspects of hemophilia in Iran, the molecular 
studies are limited and only a few Iranian cases 
underwent genetic investigations (7). Therefore, the 
current study aimed to analyze the underlying gene 
defect of 10 Iranian patients with hemophilia B which 
was performed by the Sanger sequencing method. We 
also assessed the laboratory findings and clinical 
presentations of the studied subjects. 
 
Methods 
Patients and data collection: This study was 
conducted on 10 unrelated patients with previously 
diagnosed hemophilia B. The parents of all patients 
were requested to fill a written consent and the study 
was approved by the Medical Ethics Committee of 
Iran University of Medical Sciences. Patients were 
carefully examined by a hematologist and their 
clinical presentations and previous medical history 
were thoroughly recorded. Demographic data 
including age, sex, and consanguinity were extracted 
from medical documents or by interview.  
Primary laboratory investigations including 
prothrombin time (PT) and activated partial 
thromboplastin time (APTT) were conducted by 
coagulation analyzer (STart; Stago, Paris, France) 
using Diagnostica Stago-France kits. FIX activity 
(FIX: C) and FIX antigen (FIX: Ag) levels were also 
performed for patients. FIX activity assay was carried 
out by one-stage PTT-based assay by the STA 
compact automatic coagulometer (Stago) and using 
Diagnostica Stago, Franconville, France kit. 
Furthermore, the ELISA method (ELISA; Diagnostica 
Stago) was applied for the assessment of FIX antigen 
level. The severity of disorder was categorized based 
on the FIX activity level (severe: <1%, moderate: 1-
5%, mild: 6-40% FIX activity). For identifying the 
development of FIX inhibitory antibody, a mixing 
study was performed.  
Molecular analysis and sequencing: Genomic DNA 
was extracted from the whole blood obtained in 
EDTA anticoagulant, using a DNA extraction kit 
(TakapooZist, Iran), based on the manufacture’s 
principle. The promoter and all eight exons of the F9 
gene were subjected to amplification by polymerase 
chain reaction (PCR) (Bio-Rad, UK) and specific 
primers that were designed by Oligo 7 (Molecular 
Biology Insights Inc, Cascade, CO). The primer 
sequences are indicated in table 1. Gel electrophoresis 
with 1% agarose was used to assess the PCR-
amplified fragments. Finally, the PCR products were 
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sequenced by the Sanger sequencing method using 
ABI PRISM 3700 DNA Analyzer (Applied 
Biosystems, Foster City, California, USA). Analysis 
of the obtained data was performed through Chromas 
and CLC sequence viewer software. Detected 
mutations were searched in ‘http://www.factorix.org’, 
a FIX mutation database (8) for more details. 
 
Results 
Characteristics of patients:  All patients were male 
and were diagnosed with hemophilia B before the age 
of 2 years. At the time of this study, the mean age of 
participants was 4 years, ranging from 9 months to 16 
years. Eight patients were from a consanguineous 
marriage. All patients were treated with on-demand 
factor IX concentrate and one patient developed an 
anti-FIX inhibitory antibody. The results of APTT 
were prolonged in all patients, and the PT results were 
normal. Seven patients had a severe hemophilia B 
with FIX: C <1%, while the other three cases were 
represented with moderate disease (FIX: C 1-5%). 
The most frequent clinical manifestations among 
participants were hematoma (90%), epistaxis (80%), 
and hemarthrosis (70%). Other clinical findings 
include hematuria (20%), gum bleeding (20%), and 
delay in wound healing (10%). Demographic data, 
laboratory findings, and clinical features of studied 
patients are provided in Table 2. 
Molecular findings: In nine out of 10 patients we 
detected a mutation in the F9 gene. However, no 
mutation was found in one patient, despite the 
sequencing of all 8 exons and the gene promoter, 
which may be due to the presence of mutations in the 
regions that are not routinely sequenced. The majority 
of mutations (6 cases) were observed in exon eight, 
the largest exon, and the other mutations were in 
exons 2 and 4. No one had a genetic mutation in the 
promoter region of the F9 gene. 
 
 
Figure 1. The sequence diagram of detected mutations obtained by Chromas software. 
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All detected mutations with their characteristics are 
shown in table 3. Mutation nomenclature was based 
on the Human Genome Variation Society (HGVS) 
guideline. Two types of mutation were detected in our 
participants including missense and nonsense 
mutations that were identified in 4 and 5 patients, 
respectively. Based on the FIX variant database 
(http://www.factorix.org), five mutations have been 
reported previously, but mutation c.1007T>A which 
results in p.Ile336Asn substitution seems to be a 
novel mutation. Figure-1 illustrates the sequence 
diagram of all identified mutations obtained by 
Chromas software. 
In two patients with the same mutation 
(c.304T>C), a polymorphism in intron 1 
(c.88+75A>G, 192A>G) was also detected. This 
polymorphism was previously reported in a Japanese 
individual and is not a disease-causing variation (9). 
 
Discussion 
Hemophilia B is a bleeding disorder due to 
coagulation FIX deficiency because of F9 gene 
mutations. Underlying mutations are usually 
classified as type I and type II mutations which are 
indicative of quantitative deficiency and functional 
defect, respectively (2). Mutations may occur 
throughout the F9 gene, including the promoter, 3’ 
and 5’ untranslated regions (UTR), and all the eight 
exons and seven introns, although a vast number of 
mutations (approximately 37%) involve exon 8 which 
encodes for a part of the serine protease region (8). 
Furthermore, specific nucleotides in the F9 gene are 
more susceptible to be mutated and are known as hot 
spot regions. 
In contrast to hemophilia A in which 
rearrangements, particularly intron 22 inversions, are 
the most frequent gene defect, the majority of 
mutations causing hemophilia B are point mutations 
that comprise about 64% of all reported mutations (2, 
3). Point mutations include missense mutations which 
give rise to an amino acid exchange, nonsense 
mutations leading to premature termination of 
translation because of an early stop codon, and 
splicing defects. If point mutations involve the 
regulation region, it may result in an altered gene 
expression level (4).  
According to the reported mutations in Iranian 
Table 1: The primer sequences used for PCR amplification. 
 
Region  Forward primer  Reverse primer  Product size  
Promoter  AGGACAAAAGACAAGCTACAGG TGTTCACGCGCTGCATAACCT 529 
Exon 1 CCACTGCCCATTCTCTTCACT AGAGACACACCTCATTACATAC 743 
Exon 2 GCTCCATGCCCTAAAGAGAAA TGCTTACCAACATACTGCTTCC 515 
Exon 3 GTAGTTTTGAAGAAGCACGAG GCAAGAAGGGTAATGGGGAG 683 
Exon 4 AATGAGTATCTACAGGGGAGG GAGGGAAACTTTGAACCATGA 234 
Exon 5 CCCCAATGTATATTTGACCC AAGGAAGCAGATTCAAGTAGG 330 
Exon 6 ATCATAAGCAGCAGAAGTCCC TAAAATAGCCTCAGTCTCCC 707 
Exon 7 GCTTCCCTGTCTCTCATTGT TGACCCTTCTGCCTTTAGCC 470 
Exon 8 (1) CAGCATGAGTGAACAGAACC GACATGAATCTCTACCTCCT 601 
Exon 8 (2) TTCCACTTGTTGACCGAGCC GATTGAGGAATAGGGTAGAGG 792 
Exon 8 (3) CCCGATCTTCTTTGCTTCTCC CTCTGAACACTGCTGAAGACAC 778 
Exon 8 (4) ACAGCTAGTAGAGACTTTGAGG AAGGAACTAGCAAGAGTGAGG 480 
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patients, missense mutations are the most frequently 
detected mutations in Hemophilia B which comprises 
more than 50% of all reported mutations in most of 
the studies. The second common mutation in Iranian 
hemophilia B patients is nonsense mutations (7). 
However, the results of the molecular defects of 
hemophilia B in Iran are limited. The largest study 
was conducted by Karimipoor et al on 76 unrelated 
patients with hemophilia B. Mutations were found in 
52 out of 76 studied cases and include 33 missense 
mutations, 11 nonsense mutations, 4 mutations 
affecting the promoter region, 2 frameshifts, and 2 
splicing defects (10). Here we found genetic defects 
in 9 out of 10 patients by Sanger sequencing which is 
indicative of the acceptable efficiency of this method. 
All the detected mutations were point mutations and 
with missense or nonsense effects, which are 
inconsistent with the previous reports. As could be 
expected, most of the mutations involved exon 8 and 
affects the serine protease domain of the protein. It 
has been indicated that there is a high rate of 
heterogeneity in the genetic defects of hemophilia B 
and therefore there is not a recurring mutation that 
can be used for the detection of carriers in different 
ethnicities (7). Furthermore, a genotype-phenotype 
heterogeneity is also reported in hemophilia B, and so 
























20 M Yes  
(first relation) 
10 52 <1 2  Severe  Epistaxis  Epistaxis, gums 
bleeding, hematoma 
2 4 Y 1 Y No 10 >60 <1 4  Severe Hematoma  Hematuria, 
hematoma, 
hemarthrosis 
3* 16 Y 6 M Yes 
 (first relation) 





14 M Yes 
(first relation) 
8 >60 4 8  Moderate  Hemarthrosis  Hematoma, 
hemarthrosis 
5 5 Y 2 Y Yes 
(second relation) 
9 49 <1 6  Severe Delay in 




in wound healing 
6 19 
M 
1 Y Yes 
(first relation) 
10 >60 <1 1  Severe Hematoma  Epistaxis, hematoma 
7 5 Y 2 Y No 10 52 <1 3  Severe Epistaxis  Epistaxis, 
hemarthrosis, gum 
bleeding 
8 9 M 6 M Yes 
(second relation) 





8 M Yes 
(first relation) 





1 Y Yes 
(second relation) 




* Patient number 3 developed anti FIX antibody.  
Y: year, M: month, s: second 
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different phenotypes and disease severities may be 
induced by the same mutation (11). This finding can 
also be elucidated from our study, as two mutations 
including c.892C>T and c.1113C>A were associated 
with severe and moderated disease severities. 
Furthermore, only one of the two patients affected by 
the c.892C>T (p.Arg298Stop) nonsense mutation 
developed an anti-FIX inhibitor (patient number 3 
with a severe phenotype). The risk of inhibitor 
development in hemophilia B is much less frequent 
compared with hemophilia A. Inhibitors are reported 
in about 2% of patients with hemophilia B, mainly in 
severely affected patients, and are usually associated 
with large deletions and nonsense mutations (12). 
 
Conclusion 
Our findings were suggestive of the heterogeneous 
molecular defects of hemophilia B in Iran, as 
recorded in the FIX mutation database. Moreover, no 
specific genotype-phenotype association was 
observed in studied subjects. 
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Mutation type Mutation 
effect  
Location Domain 
1, 2 10418 c.304T>C  p.Cys102Arg  Point mutation Missense Exon 4 EGF1 
3, 4 30875 c.892C>T  p.Arg298Stop  Point mutation Nonsense Exon 8 Serine Protease 
5 30990 c.1007T>A * p.Ile336Asn  Point mutation Missense Exon 8 Serine Protease 
6 6428G c.191G>A  p.Cys64Tyr  Point mutation Missense Exon 2 Gla 
7 30863 c.880C>T  p.Arg294Stop  Point mutation Nonsense Exon 8 Serine Protease 
8, 9 31096 c.1113C>A  p.Tyr371Stop  Point mutation Nonsense Exon 8 Serine Protease 
In the number 10 patient, no mutation was detected. 
* Based on the FIX mutation databases, it seems to be a novel mutation. 
 
